RNA-based Therapeutics and Vaccines Market

Global Market Study on RNA-based Therapeutics and Vaccines: Post Covid-era to bolster extensive research pertaining to RNA-based therapeutics and vaccines

RNA-based Therapeutics and Vaccines Market Segmented By RNA-based Therapeutics and RNA-based Vaccines with Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases Indication

  • May-2022
  • PMRREP12868
  • 177 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

RNA-based Therapeutics and Vaccines Market Outlook (2022-2028)

The global RNA-based therapeutics and vaccines market had witnessed a staggering CAGR of 51.6% between 2013 and 2021. As of the year 2022, it is expected to reach US$ 58.7 Mn and US$ 2.48 Bn by the year 2028, thereby recording a whopping 86.6% CAGR between 2022 and 2028.

RNA-based Therapeutics and Vaccines Market (2022)

US$ 58.7 Mn

Projected Market Value (2028)

US$ 2.48 Bn

Global Market Growth Rate (2022-2028)

86.6% CAGR

Market Share of North America and Europe

87%

Find Out More about the Report Coverage

Companies

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corp.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics
  • Moderna Therapeutics, Inc.
  • Quark Pharmaceuticals, Inc.
  • Santaris Pharma A/S (A Roche Company)
  • Sylentis S.A.

RNA-based Therapeutics and Vaccines Demand Analysis (2019 – 2022) v/s Market Outlook (2022 – 2028)

The global RNA-based Therapeutics and Vaccines Market was valued at US$ 8.99 Mn in the year 2019. It is expected to grow almost six-fold by the year 2022.

RNA therapeutics consist of 4 types – RNA aptamers, RNA interference (RNAi), antisense RNA (asRNA), and messenger RNA (mRNA). Out of these, therapy based on mRNA is the only one wherein protein synthesis gets triggered within the cells. This renders it useful in development of vaccine.

RNA-based therapeutics and vaccines started tasting success during early 2010s. The years 2020 and 2021 saw development of mRNA vaccines for mitigating Covid-19 pandemic. The very first mRNA vaccine duly approved by medicines regulator was Pfizer-BioNTech Covid-19 vaccine. Moderna Covid-19 vaccine followed suit.

It is a known fact that the features looked upon with regards to ideal delivery of drugs include biocompatibility, controlled distribution (location and persistence), guarding against nucleases, and safety.

As of the year 2022, the Asia-Pacific accounts for 10.4% of the RNA-based Therapeutics and Vaccines market. This percentage is bound to increase in the forecast period with increasing awareness amongst the people and extensive funding from the developing economies herein.

rna-based-therapeutics-and-vaccines-market

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

What’s the Scope Of RNA-Based Therapeutics and Vaccines Market?

“Oncology to Be the Focal Point of RNA-Based Therapeutics and Vaccines Market”

RNA-based therapeutics and vaccines, better known as RNA-based biopharmaceuticals, come across as a refined type of treatment and prophylactic for numerous rare and chronic ailments inclusive of cancer, tuberculosis, diabetes, and cardiovascular diseases.

Research states that out of nearly 700 RNA and DNA therapeutics in pipeline, around 430 are in initial stages of development. On the top of that, close to 35% are emphasizing on oncology. At the global level, there are approximately 65 universities and 160 organizations into development of therapies based on RNA.

North America and Europe (combined) are expected to be worth US$ 51.07 Mn in the year 2022.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

How does the RNA-based Therapeutics and Vaccines Market turn Productive for the Manufacturers?

“Manufacturers to Ride on Stability Provided by RNA Therapeutics and Vaccines”

RNA therapeutics and vaccines hold the distinction of providing better stability as compared to their counterparts. Though majority of them are under trials (as mentioned above), they are being increasingly preferred when it comes to treat obstinate disorders. The technologies that are being readily adopted include Smart technology, antisense technology, and RNAi interference technology. RNAi and antisense technology have been drawing attention of the researchers as they help in provision of base sequence for producing RNA drugs. However, it should not be inferred that both the technologies have the same way of functioning. Antisense technology works by creation of RNA strand from a known gene sequence, whereas RNAi technology implies destruction of specific mRNA molecules.

Explore Persistence Market Research’s expertise in promulgation of the business !

Which Factors are restraining the RNA-based Therapeutics and Vaccines Market?

“Expensive Research to be the Major Restraint”

RNA-based therapeutics and vaccines market is subject to costly research, followed by higher rate of failure during clinical trials. Also, issues regarding drug delivery can’t be ruled out. Higher costs involved in research could compel the under-developed economies to give a second thought regarding making investments into this market.

How about Insights Country-wise?

“The US to Dominate the RNA-based Therapeutics and Vaccines Market”

The US is on the top pedestal as far as RNA-based therapeutics and vaccines market is concerned. This could be reasoned with quick adaptation to technologies coupled with growing incidences of chronic diseases. Plus, a handsome investment is being done in research by the government regarding advancements in the RNA-based technologies.

Coming to Europe, Germany, the UK, and Belgium rule the market due to continuous advancements on the technological front.

The Asia-Pacific is expected to hold a significant market share in the forecast period due to the market players drawing realization that overheads come out to be less.

How Does the Categorization of RNA-based Therapeutics and Vaccines Market go?

“The Market categorized based on Type of Product, Application, and End-user”

The RNA-based Therapeutics and Vaccines Market, by application, spans research applications, diagnostic testing, and clinical testing. By end-user, it’s diagnostic centers, hospitals, academic & research institutes, forensic science laboratories, and CROs (Contract Research Organizations). By type of product, it’s workstations, reagents and consumables, and kits (RNA sample preparation and DNA sample preparation).

Which Categories Hold the Largest Market Share?

“Clinical Testing, Academic & Research Institutes, and Kits leading from the Front”

These days, clinical testing is the need of the hour, as various chronic ailments, and most importantly, the pandemic needs to be brought under control. The academic & research institutes are engaged in their entirety in lending a constructively helping hand in RNA-based therapeutics and vaccines. Kits are preferred as the holistic package serves a greater purpose, including the history and the then course of action. However, they should be kept away from contamination, or else the analysis won’t be precise.

How has Covid-19 impacted the Market?

“Covid-19 having left No Stone Unturned in Keeping the Market on the Toes”

The healthcare vertical has witnessed maximum turmoils during the pandemic, and they do not seem to stop any time soon. Research is being conducted in almost every part of the developed world regarding the ways in which Covid-19 could be brought under control. Now that the world is grappling with the third wave in the form of Omicron variant, there is no relaxation for RNA-based therapeutics and vaccines. The only major difference is that with chronic diseases, Covid-19 has also figured in the list of “mandatory combating of diseases”.

Competitive Landscape

The key players are going for every possible mode of expansion, inclusive of mergers, acquisitions, new therapeutics’ and vaccines’ launch, joint ventures, partnerships,, and likewise for making a mark in the market.

One such development is as follows –

  • Pifizer, on January 10, 2022, inked a “development and Option Agreement” with Acuitas Therapeutics, which will allow Pfizer to license the latter’s LNP technology for close to 10 targets for therapeutics’ or vaccines’ development. This would be on a non-exclusive basis.

RNA-based Therapeutics and Vaccines Industry Report Scope

Attribute

Details

Forecast Period

2022-2028

Historical Data Available for

2013-2021

Market Analysis

US$ Mn/Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • LATAM
  • The Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Benelux
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Singapore
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • Egypt
  • North Africa
  • South Africa
  • GCC Countries

Key Market Segments Covered

  • Working Type
  • Frequency Band
  • Application
  • Region

Key Companies Profiled

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corp.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics
  • Moderna Therapeutics, Inc.
  • Quark Pharmaceuticals, Inc.
  • Santaris Pharma A/S (A Roche Company)
  • Sylentis S.A.

Pricing

Available upon Request

Key Segments Covered in RNA-based Therapeutics and Vaccines Market

RNA-based Therapeutics and Vaccines Market by Type of Product

  • Workstations
  • Reagents and Consumables
  • Kits (RNA sample preparation and DNA sample preparation)

RNA-based Therapeutics and Vaccines Market by Application

  • Research Applications
  • Diagnostic Testing
  • Clinical Testing

RNA-based Therapeutics and Vaccines Market by End User

  • Diagnostic Centers
  • Hospitals
  • Academic & Research Institutes
  • Forensic Science Laboratories
  • CROs (Contract Research Organizations)

RNA-based Therapeutics and Vaccines Market by Region

  • North America RNA-based Therapeutics and Vaccines Market
  • Latin America RNA-based Therapeutics and Vaccines Market
  • Europe RNA-based Therapeutics and Vaccines Market
  • Asia-Pacific RNA-based Therapeutics and Vaccines Market
  • Middle East & Africa (MEA) RNA-based Therapeutics and Vaccines Market

Media Release

- FAQs -

The RNA-based Therapeutics and Vaccines Market is expected to be worth US$ 58.7 Mn in the year 2022 and grow 42.1 times by the year 2028.

The market for RNA-based Therapeutics and Vaccines is expected to reach US$ 2.48 Bn by 2028, expanding at a CAGR of 86.6%.

North America is one of the highest revenue generators for RNA-based Therapeutics and Vaccines, accounting for 46.2% of the global market share.

Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., Regulus Therapeutics, Inc., Marina Biotech, Inc., miRagen Therapeutics, Moderna Therapeutics, Inc., Quark Pharmaceuticals, Inc., Santaris Pharma A/S (A Roche Company), and Sylentis S.A.

The Asia-Pacific’s RNA-based Therapeutics and Vaccines market holds 10.4% of the market share.

Recommendations

Elder Care Products Market

Elder Care Products Market projected to expand at a healthy 5.4% CAGR, global industry valuation is set to reach US$ 38.61 Bn by the end of 2032..

Non Infectious Macular Edema Treatment Market

Non Infectious Macular Edema Treatment Market at a CAGR of 7.0% during the forecast period 2018-2026. The study also projects the market to reach a valuation of over US$ 17,200 Mn by the end of 2026..

Osteoarthritis Market

Due to advancements in technology, osteoarthritis management becomes more focused on effective treatment and this is expected to fuel the growth of the global osteoarthritis treatment market in the long run..

Metagenomics Market

With technological advancements, many new bioinformatics tools have been introduced in the market, which is expected to contribute to the growth of the metagenomics market. .

Our Clients

Our Clients